; (II) to support innovative candidate products in preclinical and clinical development that reduce antimicrobial resistance; and (III) to support research with respect to infection prevention and control to slow the spread of resistant bacteria, fungi, and viruses. (ii) References Except as otherwise specified, any reference to the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator or the CARB-X program in any statute, Executive order, rule, regulation, directive, or other Federal document is deemed to be a reference to the Combating Antimicrobial Resistance Biopharmaceutical Accelerator Program under this subparagraph. (iii) Authorization of appropriations (I) In general To carry out the program under clause (i), there is authorized to be appropriated $500,000,000 for the period of fiscal years 2024 through 2028, to remain available until expended. (II) Requirement Of the amounts made available to carry out the program under clause (i) for the period of fiscal years 2024 through 2028, not less than 20 percent shall be used to support antifungal product development. .